S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
The Small Biotech Scaring Big Pharma (Ad)
No OPEC+ oil shakeup as Russian price cap stirs uncertainty
OPEC doesn't change its targets for oil production amid uncertainty over new Western price cap on Russian oil
Why Your IRA Could Crash on January 16th? (Ad)
As Musk is learning, content moderation is a messy job
Reformers take 6 of 14 UAW board seats, could win majority
Why Your IRA Could Crash on January 16th? (Ad)
FDA change ushers in cheaper, easier-to-get hearing aids
OPEC keeps oil targets amid uncertainty on Russian sanctions
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
The Small Biotech Scaring Big Pharma (Ad)
No OPEC+ oil shakeup as Russian price cap stirs uncertainty
OPEC doesn't change its targets for oil production amid uncertainty over new Western price cap on Russian oil
Why Your IRA Could Crash on January 16th? (Ad)
As Musk is learning, content moderation is a messy job
Reformers take 6 of 14 UAW board seats, could win majority
Why Your IRA Could Crash on January 16th? (Ad)
FDA change ushers in cheaper, easier-to-get hearing aids
OPEC keeps oil targets amid uncertainty on Russian sanctions
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
The Small Biotech Scaring Big Pharma (Ad)
No OPEC+ oil shakeup as Russian price cap stirs uncertainty
OPEC doesn't change its targets for oil production amid uncertainty over new Western price cap on Russian oil
Why Your IRA Could Crash on January 16th? (Ad)
As Musk is learning, content moderation is a messy job
Reformers take 6 of 14 UAW board seats, could win majority
Why Your IRA Could Crash on January 16th? (Ad)
FDA change ushers in cheaper, easier-to-get hearing aids
OPEC keeps oil targets amid uncertainty on Russian sanctions
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
The Small Biotech Scaring Big Pharma (Ad)
No OPEC+ oil shakeup as Russian price cap stirs uncertainty
OPEC doesn't change its targets for oil production amid uncertainty over new Western price cap on Russian oil
Why Your IRA Could Crash on January 16th? (Ad)
As Musk is learning, content moderation is a messy job
Reformers take 6 of 14 UAW board seats, could win majority
Why Your IRA Could Crash on January 16th? (Ad)
FDA change ushers in cheaper, easier-to-get hearing aids
OPEC keeps oil targets amid uncertainty on Russian sanctions

GSK - GSK Stock Forecast, Price & News

$35.35
+0.32 (+0.91%)
(As of 12/2/2022 12:00 AM ET)
Add
Compare
Today's Range
$34.91
$35.47
50-Day Range
$28.66
$35.35
52-Week Range
$28.47
$46.97
Volume
4.89 million shs
Average Volume
5.06 million shs
Market Capitalization
$71.89 billion
P/E Ratio
4.33
Dividend Yield
3.50%
Price Target
N/A

GSK MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
0.60% of Float Sold Short
Dividend Strength
Moderate
Based on Four Factors
Sustainability
N/A
News Sentiment
0.06mentions of GSK in the last 14 days
Based on 11 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
4.29%
From $3.26 to $3.40 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.25 out of 5 stars

Medical Sector

239th out of 1,034 stocks

Pharmaceutical Preparations Industry

98th out of 502 stocks

GSK stock logo

About GSK (NYSE:GSK) Stock

GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; Progentec Diagnostics, Inc.; Alector, Inc.; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

Receive GSK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GSK and its competitors with MarketBeat's FREE daily newsletter.

GSK Stock News Headlines

Cosmos Holdings May be a Long-Term Buy with Short-Term Risk (GSK)
Cosmos Holdings stock is up 618% in November likely due to a short squeeze. This article explains why Cosmos Holdings may still be a good long-term investment
GSK (NYSE:GSK) PT Lowered to GBX 1,550
Should You Hold GSK plc (GSK) Shares?
GSK (NYSE:GSK) Price Target Lowered to GBX 1,535 at Morgan Stanley
GSK Shares Drop as Cancer Drug Disappoints
GSK's Q3 Earnings Beat, Ups 2022 Sales Outlook, Stock Up
See More Headlines
Receive GSK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GSK and its competitors with MarketBeat's FREE daily newsletter.

GSK Company Calendar

Ex-Dividend for 10/6 Dividend
8/18/2022
Dividend Payable
10/06/2022
Last Earnings
11/02/2022
Ex-Dividend for 1/12 Dividend
11/17/2022
Today
12/04/2022
Fiscal Year End
12/31/2022
Dividend Payable
1/12/2023
Next Earnings (Estimated)
2/08/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Employees
90,096
Year Founded
2000

Profitability

Net Income
$6.03 billion
Pretax Margin
15.33%

Debt

Sales & Book Value

Annual Sales
$46.91 billion
Cash Flow
$3.61 per share
Book Value
$5.05 per share

Miscellaneous

Outstanding Shares
2,033,680,000
Free Float
1,830,309,000
Market Cap
$71.89 billion
Optionable
Optionable
Beta
0.68

Social Links


Key Executives

  • Ms. Emma Natasha Walmsley (Age 52)
    CEO & Director
    Comp: $4.61M
  • Mr. Iain James MackayMr. Iain James Mackay (Age 60)
    CFO & Exec. Director
    Comp: $3.43M
  • Ms. Julie Brown (Age 60)
    Chief Financial Officer
  • Ms. Shobie Ramakrishnan
    Chief Digital & Technology Officer
  • Mr. Tony Wood
    Chief Scientific Officer
  • Ms. Sarah Elton-Farr
    Head of Investor Relations
  • Mr. James Ford
    Sr. VP & Group Gen. Counsel of Legal & Compliance
  • Ms. Sally JacksonMs. Sally Jackson
    Sr. VP of Global Communications & CEO Office
  • Ms. Diana Conrad
    Chief People Officer
  • Mr. David Simon Redfern (Age 56)
    Chief Strategy Officer













GSK Stock - Frequently Asked Questions

Should I buy or sell GSK stock right now?

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for GSK in the last twelve months. There are currently 2 sell ratings, 6 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" GSK shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GSK, but not buy additional shares or sell existing shares.
View GSK analyst ratings
or view top-rated stocks.

How have GSK shares performed in 2022?

GSK's stock was trading at $44.10 at the beginning of the year. Since then, GSK stock has decreased by 19.8% and is now trading at $35.35.
View the best growth stocks for 2022 here
.

Are investors shorting GSK?

GSK saw a drop in short interest in November. As of November 15th, there was short interest totaling 11,250,000 shares, a drop of 15.8% from the October 31st total of 13,360,000 shares. Based on an average daily trading volume, of 6,330,000 shares, the days-to-cover ratio is presently 1.8 days. Approximately 0.6% of the company's stock are sold short.
View GSK's Short Interest
.

When is GSK's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 8th 2023.
View our GSK earnings forecast
.

How were GSK's earnings last quarter?

GSK plc (NYSE:GSK) released its quarterly earnings data on Wednesday, November, 2nd. The pharmaceutical company reported $1.09 earnings per share for the quarter, beating analysts' consensus estimates of $0.90 by $0.19. The pharmaceutical company had revenue of $9.22 billion for the quarter, compared to the consensus estimate of $7.75 billion. GSK had a net margin of 37.88% and a trailing twelve-month return on equity of 32.18%.

How often does GSK pay dividends? What is the dividend yield for GSK?

GSK declared a quarterly dividend on Wednesday, November 2nd. Shareholders of record on Friday, November 18th will be paid a dividend of $0.3695 per share on Thursday, January 12th. This represents a $1.48 annualized dividend and a dividend yield of 4.18%. The ex-dividend date of this dividend is Thursday, November 17th.
Read our dividend analysis for GSK
.

Is GSK a good dividend stock?

GSK (NYSE:GSK) pays an annual dividend of $1.24 per share and currently has a dividend yield of 3.50%. The dividend payout ratio is 15.20%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, GSK will have a dividend payout ratio of 36.47% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for GSK.

What guidance has GSK issued on next quarter's earnings?

GSK issued an update on its FY 2022 earnings guidance on Wednesday, November, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $50.67 billion-$51.60 billion, compared to the consensus revenue estimate of $32.29 billion.

What other stocks do shareholders of GSK own?

Based on aggregate information from My MarketBeat watchlists, some companies that other GSK investors own include AT&T (T), Pfizer (PFE), Johnson & Johnson (JNJ), Verizon Communications (VZ), Cisco Systems (CSCO), AbbVie (ABBV), Intel (INTC), Gilead Sciences (GILD), Walt Disney (DIS) and NVIDIA (NVDA).

What is GSK's stock symbol?

GSK trades on the New York Stock Exchange (NYSE) under the ticker symbol "GSK."

Who are GSK's major shareholders?

GSK's stock is owned by many different retail and institutional investors. Top institutional investors include Fisher Asset Management LLC (0.60%), Price T Rowe Associates Inc. MD (0.55%), Renaissance Technologies LLC (0.46%), State Street Corp (0.37%), Two Sigma Investments LP (0.35%) and JTC Employer Solutions Trustee Ltd (0.23%).
View institutional ownership trends
.

How do I buy shares of GSK?

Shares of GSK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is GSK's stock price today?

One share of GSK stock can currently be purchased for approximately $35.35.

How much money does GSK make?

GSK (NYSE:GSK) has a market capitalization of $71.89 billion and generates $46.91 billion in revenue each year. The pharmaceutical company earns $6.03 billion in net income (profit) each year or $8.16 on an earnings per share basis.

How many employees does GSK have?

The company employs 90,096 workers across the globe.

How can I contact GSK?

GSK's mailing address is 980 GREAT WEST ROAD, BRENTFORD X0, TW8 9GS. The official website for the company is www.gsk.com. The pharmaceutical company can be reached via phone at 442080475000, via email at gsk.investor-relations@gsk.com, or via fax at 44-20-8047-7807.

This page (NYSE:GSK) was last updated on 12/4/2022 by MarketBeat.com Staff